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Summary
Background: Major characteristics of symptomatic patients with heart failure are
exercise intolerance, poor prognosis, and poor quality of life (QOL). However, most
QOL questionnaires are applicable for patients with mild to moderate heart failure,
and are not sufﬁciently sensitive to discriminate between patients with NYHA classes
III and IV. Therefore, it is necessary to prepare a questionnaire focused on patients
with severe heart failure.
Objectives: We developed a Japanese version of the Maugeri Foundation Respiratory
Failure (MRF28) questionnaire and assessed validity and reliability of MRF28 in heart
failure patients.
Methods: The MRF28 questionnaire was evaluated in 124 patients with heart failure
(NYHA classes: I, 24; II, 31; III, 52; IV, 17). Reliability was evaluated by internal
consistency and test—retest reliability. Validity was determined by correlation with
World Health Organization Quality of Life (WHOQOL) questionnaire and physiological
parameters.
Results: The MRF28 showed high internal consistency and reproducibility. The total
score and subscores were all increased with the progress of heart failure. The total
score could differentiate patients among NYHA II, III, and IV, but could not between
NYHA I and II. However, all subscores and total score changed consistently with
changes in symptoms of heart failure.
∗ Corresponding author. Tel.: +81 76 434 7297; fax: +81 76 434 5026.
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0914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.jjcc.2008.09.011
118 M. Hatta et al.
Conclusion: MRF28 is a valid and reliable disease-speciﬁc questionnaire for assessing
QOL in symptomatic patients with heart failure. Thus, this questionnaire may be useful
for a QOL evaluation of patients with moderate to severe heart failure.
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WHOQOL questionnaire
A Japanese version of the World Health Organi-© 2008 Japanese Colleg
reserved.
Introduction
Major characteristics of symptomatic patients with
heart failure are exercise intolerance, poor prog-
nosis, and poor quality of life (QOL). So far,
several approaches to determine disease-speciﬁc
QOL in heart failure patients have been developed.
The Minnesota Living Heart Failure Questionnaire
has been widely used in many randomized tri-
als for heart failure patients among drug studies
[1]. The Chronic Heart Failure Questionnaire or
Kansas City Cardiomyopathy Questionnaire was
also used in some studies [2,3]. However, most
of these QOL questionnaires are applicable to
patients with mild to moderate heart failure,
and are not sufﬁciently sensitive to discriminate
between patients with NYHA classes III and IV
[4,5]. Therefore, it is necessary to prepare a ques-
tionnaire focused on patients with severe heart
failure.
Like patients with severe heart failure, those
with respiratory failure also have signs due to respi-
ratory distress, exertional dyspnea, orthopnea, and
dyspnea at rest. Because cardiac dyspnea is very
similar to pulmonary dyspnea, the differentiation is
not easy without clinical evidence of these diseases
[6]. A recent study showed that dyspnea-related
symptoms have an impact on functional capacity
and QOL in both diseases [7]. Thus, it may be rea-
sonable to use QOL questionnaires developed for
patients with respiratory failure and for those with
severe heart failure.
Here, we developed a Japanese version of the
Maugeri Foundation Respiratory Failure (MRF28)
questionnaire, which was conventionally developed
for the evaluation of patients with chronic res-
piratory failure [8—11]. Because MRF28 contains
domains of ‘daily activity,’ ‘cognition,’ and ‘inva-
lidity’ which are all closely associated with the
severity of heart failure, the application of MRF28
seemed to be reasonable to evaluate their health-
related QOL.
The purpose of the present study was to assess
the validity, reliability, and clinical effectiveness
of a Japanese version of MRF28 in patients with
symptomatic heart failure. We found that this
questionnaire could be useful as one of the QOL
evaluation methods for patients with mild to severe
heart failure.
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laboration of the Japanese translation
hree Japanese translations of the original English
ersion were made by three bilingual translators;
rom these three versions, a panel of physi-
ians elaborated a second version, which was
ack-translated to English by a bilingual physician
linded to the original English version. Both English
ersions were compared for coherence to detect
he presence of ambiguous or inadequate items,
nd minor changes were made to produce the ﬁnal
apanese version. It is this version that was submit-
ed to the validation process (present study).
he MRF28 questionnaire
he MRF28 is a 28-item, disease-speciﬁc, health-
elated QOL questionnaire for patients with chronic
espiratory failure due to pulmonary diseases and
as been validated in Italian and French [8,9]
see Appendix A). It is self-administered and easy
o complete with all items being answered with
ither ‘yes’ or ‘no.’ It includes 28 questions which
re coded to compute 3 subscores (‘daily activity’
ased on 11 items, ‘cognitive function’ based on 4
tems, and ‘invalidity’ based on 5 items) and a total
core. For applying this questionnaire to patients
ith heart diseases, we omitted the words ‘lung’
nd ‘respiratory’ in each sentence. Each positive
esponse to an item is rated as ‘1,’ and each nega-
ive response as ‘0;’ the item and total scores are
hen summed up and expressed as a percentage of
he maximum positive score. The ﬁnal scores range
rom 0 to 28 with higher scores reﬂecting a higher
egree of impairment. MRF28 also indicated their
eneral and respiratory health using two 5-point
cales. These two scales each had ﬁve categories:
very good,’ ‘good,’ ‘satisfactory,’ ‘poor,’ and ‘very
oor.’ation (WHO) QOL questionnaire [12], known as
generic health-related QOL questionnaire, was
lso used to determine the usefulness of MRF28
n all patients. It is self-administered and easy to
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omplete with all items being answered with 5-
oint scale. The WHOQOL questionnaire comprises
6 items, which measure the following broad
omains: physical health, psychological health,
ocial relationships, and environment. It is conve-
ient for use in clinical trials (http://www.who.int/
ubstance abuse/research tools/en/english
hoqol.pdf). The scores of each domain and
verage scores range from 1 to 5 with lower scores
eﬂecting a higher degree of impairment.
peciﬁc activity scale
e also evaluated daily activity quantitatively
ith a speciﬁc activity scale (SAS) [13]. The scale
an express the maximal physical activities with
n energy cost spent of the patient. By deﬁ-
ition, 1MET is equivalent to a metabolic rate
onsuming 3.5ml of oxygen/kg of body weight/min.
he SAS contains questions about speciﬁc physi-
al activities that a patient would perform in daily
ife. Each patient was asked to specify whether
e or she could perform each type of activity
ithout symptomatic limitation. Summarizing the
uestionnaire data, a given number of metabolic
osts (=SAS) were derived for each patient regard-
ng the self-perceived exercise tolerance. Lower
cores reﬂect a higher degree of impairment. Inter-
bserver variability of speciﬁc activity scale was
.4± 0.5METs, suggesting that changes in func-
ional capacity ≥1MET are reliable and clinically
elevant [13].
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Table 1 Baseline characteristics of study population.
NYHA functional class
All (n = 124) I (n = 24)
Gender (male/female) 86/38 20/4
Age (years)§ 67± 11 59± 12
BMI§ 23.0± 3.5 25.2± 3.5
Underlying heart disease
Ischemic 24 5
Non-ischemic 9 19
SAS (METs)§ 4.2± 2.2 7.4± 0.5
SpO2 (%)§ 95± 4 97± 1
BNP (pg/ml)§ 527± 653 65± 88
Hb (g/dl)§ 13.0± 2.2 14.5± 1.7
Cre (mg/dl)§ 1.1± 0.4 0.9± 0.2
Values are number of patients or mean± S.D. BNP, B-type natriuret
Heart Association; SAS, speciﬁc activity scale; SpO2, arterial oxyge
* p < 0.01 vs. NYHA I.
# p < 0.01 vs. NYHA II.
$ p < 0.01 vs. NYHA III.
§ p < 0.01 among four groups with the Jonckheere—Terpstra test.119
ubjects
his study included 100 patients with symptomatic
eart failure (66 men and 34 women; mean age,
9± 10 years) and 24 patients with asymptomatic
ut previously symptomatic heart failure (Table 1).
atients with acute coronary syndrome, pulmonary
ypertension, moderate to severe pulmonary dis-
ases, chronic renal failure treated with dialysis
Cre > 2.0mg/dl), and anemia (Hb < 8.0 g/dl) were
xcluded. Patients who had symptoms of angina
ere also excluded in this study because it was dif-
cult to reliably distinguish from symptoms due to
eart failure. No patient used non-invasive pres-
ure positive airway support before and during
his study. All patients provided written, informed
onsent, and the study was approved by the Insti-
utional Review Board of our University.
tudy protocol
ll subjects answered the questionnaire of MRF28,
HOQOL, and SAS on the same day. Blood pressure,
ulse rate, arterial oxygen saturation (SpO2), blood
hemistry, and B-type natriuretic peptide (BNP)
ere also measured. After initial assessment, 60
atients were followed to determine reproducibil-
ty and responsiveness.tatistical analyses
ata are expressed as mean± standard devia-
ion unless otherwise indicated. The Jonckheere—
II (n = 31) III (n = 52) IV (n = 17)
25/6 31/21 10/7
66± 10 70± 10** 74± 10**
23.8± 3.2 22.5± 3.4 21.8± 3.9
9 7 7
22 45 10
5.5± 0.5* 3.1± 0.8*,# 1.0± 0.0*,#,$
96± 1 95± 2* 88± 5*,#,$
329± 351 669± 558* 1103± 1106*,#
13.6± 1.8 12.6± 2.2* 11.3± 2.3*,#
0.9± 0.2 1.1± 0.4 1.5± 0.7*,#,$
ic peptide; Cre, creatinine; Hb, hemoglobin; NYHA, New York
n saturation.
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TFigure 1 Histogram of distribution of scores for the
symptomatic patients (b, n = 100). NYHA, New York Heart
Terpstra test, which is a nonparametric test for
ordered difference among classes, was used to com-
pare the scores among four groups (NYHA I—IV) in
severity categories of heart failure and among three
groups that had different responses of symptoms
to treatment (‘improved,’ ‘unchanged,’ and ‘dete-
riorated’). Differences among NYHA groups were
also analysed with one-way analysis of variance
for repeated measures and Scheffe’s method for
multiple comparisons. p < 0.05 was considered sta-
tistically signiﬁcant.
Validity
To validate the MRF28, cross-sectional comparisons
were made by using WHOQOL questionnaire or
several physiological parameters. The underlying
prediction was that the MRF28 would be positively
correlated with worsening of the disease state.
Reproducibility
Data from patients, who had had changes of the
SAS less than 1MET between the ﬁrst and second
times, were used to assess the reproducibility of the
health measures. Intraclass correlation coefﬁcient
was calculated using a random effects one-way
analysis of variance. We speciﬁed before the study
that intraclass correlation coefﬁcient values of 0.75
or more would represent satisfactory reproducibil-
ity.
Responsiveness
Out of 60 patients who answered the question-
naire twice, general health perception (evaluated
with 5-point scales) was ‘improved’ in 11 patients,
‘unchanged’ in 42, and ‘deteriorated’ in 7 patients.
To evaluate the responsiveness of MRF28, we com-
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F8 total scores in all patients (a, n = 124) and limited
ciation.
ared changes of total scores, subscores, and
peciﬁc activity scale among these three groups.
esults
linical data are shown in Table 1. One hun-
red twenty-four patients with heart disease were
ncluded in this study (NYHA classes I, 24; II, 31;
II, 52; IV, 17). SAS was decreasing and BNP was
ncreasing along with the progression of heart fail-
re (p < 0.001 with Jonckheere—Terpstra test). The
verage time to answer this questionnaire was
± 3min.
istribution of MRF28 scores
he MRF28 scores covered 93% of its potential scal-
ng range (Fig. 1a). There seemed to be a slight
oor effect for MRF28, but this might be due to the
nclusion of 24 patients with asymptomatic heart
isease (NYHA I). In fact, when this evaluation was
imited to symptomatic patients (NYHA II—IV), the
istogram changed to nearly a normal distribution
Fig. 1b). Because ﬂoor effect or ceiling effect
an markedly inﬂuence sensitivity of QOL question-
aires, the discriminating properties of MRF28 are
egarded as good in symptomatic patients.
eliability
est—retest reproducibility
ixty patients were asked to answer the question-
aire again. Because the changes of SAS in 42
atients were 0.5 or 0METs, test—retest repro-
ucibility was determined in these 42 patients.
ig. 2 shows the relation between the ﬁrst MRF28
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Figure 2 Test—retest reliability. Correlation between
the initial values and the values obtained after 5 weeks
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questionnaire discriminates among NYHA groupsor the MRF28 total scores in 42 patients with heart
isease in the stable clinical condition (the change of
peciﬁc activity scales was less than 1MET).
core and the second one (mean interval, 5 weeks).
here were good correlations between subscores.
oefﬁcient of variation of the MRF28 total score was
.3%. Intraclass correlation coefﬁcient was 0.93 for
he item ‘daily activity,’ 0.77 for the item ‘cogni-
ive function,’ 0.86 for the ‘invalidity,’ and 0.94 for
he MRF28 total score. These ﬁndings indicate that
RF28 was highly reproducible among heart failure
atients.
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Table 2 Correlations between Maugeri Foundation Respir
Organization Quality of Life (WHOQOL) questionnaire or phy
MRF28
Daily activity
MRF28 factors
Daily activity 1.00
Cognition 0.37
Invalidity 0.73
Total 0.96
WHOQOL
Physical 0.74
Psychological 0.51
Social relationship 0.24
Environment 0.26
Overall 0.64
Average 0.60
NYHA class 0.80
SAS 0.82
SpO2 0.44
log10 BNP 0.52
BNP: B-type natriuretic peptide; NYHA: New York Heart Association121
nternal consistency
ronbach’s reliability coefﬁcient alpha was 0.89 for
he item ‘daily activity,’ 0.70 for the item ‘cog-
ition,’ 0.74 for the ‘invalidity,’ and 0.91 for the
RF28 total score. Only the domain of ‘cognition’
ailed to attain a high internal consistency. The
ower Cronbach’s alpha reﬂects that it is composed
f only four questions acquiring slight different
ieces of information.
alidity of the MRF28
omparison of the total score and subscores of
RF28 with WHOQOL questionnaire is shown in
able 2. All of MRF28 subscores were correlated
ith ‘physical’ domain of WHOQOL (R = 0.41—0.74),
ut not with ‘environment’ at all. The subscore
f ‘daily activity’ (R = 0.51), ‘cognition’ (R = 0.41),
nd total score (R = 0.55) also correlated well
ith ‘psychological’ domain of WHOQOL. MRF28
otal score and subscore of ‘daily activity’ were
trongly correlated with SAS (R = 0.78 and 0.82,
espectively). The subscore of ‘invalidity’ was also
orrelated with SAS (R = 0.64), but that of ‘cog-
ition’ was not (R = 0.31). MRF28 total score was
eakly correlated with log10 BNP (R = 0.45) and
pO2 (R = 0.41).
Known-group validity estimated how well theFig. 3). Total score and subscores were all
ncreasing along with the progression of heart fail-
re (p < 0.001 with Jonckheere—Terpstra test). As
xpected, the MRF28 total score and subscores
atory Failure (MRF28) questionnaire and World Health
siological parameters in all patients.
Cognition Invalidity Total
1.00
0.42 1.00
0.52 0.87 1.00
0.41 0.63 0.74
0.41 0.43 0.55
0.21 0.27 0.28
0.16 0.21 0.26
0.38 0.56 0.68
0.36 0.49 0.61
0.38 0.65 0.78
0.31 0.64 0.78
0.13 0.25 0.41
0.07 0.39 0.45
; SAS: speciﬁc activity scale; SpO2: arterial O2 saturation.
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p-Values were the result of Jonckheere—Terpstra test. M
of ‘daily activity’ clearly differentiated NYHA
functional class II from III and IV. However, the sub-
score of NYHA II was not signiﬁcantly higher than
that of NYHA I. The subscores of ‘cognition’ and
‘invalidity’ also increased as NYHA functional class
worsened (p < 0.0001 with Jonckheere—Terpstra
test), however the statistical signiﬁcance was found
only between classes II and III. Thus, the MRF28
scores and subscores can clearly discriminate NYHA
class II from III.
Responsiveness
The MRF28 and SAS yielded minimal changes in
the ‘unchanged’ group (Fig. 4). On the contrary,
the ‘improved’ group changed by −11 points of
MRF28 with 2.2METs increasing of SAS, while the
‘deteriorated’ group changed by +7 points of MRF
with 2.3METs decreasing of SAS. Consequently, the
MRF28 total score and subscores could detect dif-
ferences among the ‘unchanged,’ ‘improved,’ and
‘deteriorated’ groups (p < 0.05). These results sug-
gest that the MRF28 can provide a precise and
sensitive estimate of changes in the health status
of patients with heart failure.
e
c
a
e
[
wifferent severities of heart failure. p < 0.01, p < 0.05.
S.E.
iscussion
he present study was designed to evaluate the
linical effectiveness of the MRF28 questionnaire
or the assessment of QOL among patients with
eart failure. The MRF28 was suitable for measur-
ng the health status in patients with heart failure
ecause the validity, reliability, and responsiveness
ere all satisfactory.
The cardinal symptoms of heart failure are dysp-
ea and easy fatigability. Patients also present with
astrointestinal symptoms and peripheral edema,
esulting from ﬂuid retention. Cerebral symp-
oms can be observed in patients with severe
eart failure, particularly in elderly patients with
erebral arteriosclerosis and reduced cerebral per-
usion [6,14]. In chronic obstructive pulmonary
isease, dyspnea comes on gradually and is ﬁrst
oticed during physical exertion or during acute
xacerbations. As the disease progresses, exer-
ise tolerance becomes progressively limited. In
dvanced disease, morning headache, peripheral
dema, anxiety, and depression can be observed
15]. Like patients with severe heart failure, those
ith chronic respiratory disease also have signs
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Wigure 4 Association between changes in patients’ gene
RF28 total score, and subscores. Among 56 patients,
unchanged,’ and 6 patients as ‘deteriorated.’ p-Values w
ue to respiratory distress, exertional dyspnea,
rthopnea, and dyspnea at rest. The differentia-
ion between cardiac and pulmonary dyspnea is not
asy without clinical evidence of these diseases [6].
recent study showed that dyspnea-related symp-
oms have an impact on functional capacity and
OL in both diseases [7]. Thus, considered with the
imilarity in both diseases, it may be reasonable to
pply a QOL questionnaire for respiratory failure to
evere heart failure.
Here, we developed a Japanese version of MRF28
hich was conventionally developed for the eval-
ation of patients with chronic respiratory failure
8—11]. The questionnaire does not include ques-
ions about hemoptysis and productive sputum,
hich are not typical signs of heart failure. More-
ver, it involves three characteristic domains, ‘daily
ctivity,’ ‘cognition,’ and ‘invalidity.’ The domain
f ‘cognition’ is to evaluate how patients feel loss
f concentration or memory disturbance in their
aily life. The domain of ‘invalidity’ is to evalu-
te how patients feel loneliness or sick because of
heir disease. In the validation process, we revealed
hat not only ‘daily activity,’ but also ‘cognition’
nd ‘invalidity’ were all closely associated with the
(
c
t
uealth perception and changes in speciﬁc activity scale,
atients were classiﬁed as ‘improved,’ 42 patients as
the result of Jonckheere—Terpstra test. Mean± S.E.
everity of heart failure. For this reason, an applica-
ion of MRF28 seemed to be reasonable to evaluate
heir health-related QOL.
Generally, the validation process relies on show-
ng that the new QOL tool yields similar results
o previously established health-related QOL
nstruments and the scores are also correlated with
elevant physiological parameters [16]. The WHO-
OL, a generic questionnaire, was also applied to
atients with ischemic cardiomyopathy in the pre-
ious reports [17,18]. Therefore, we adopted the
uestionnaire for the present study. We also used
any physiological parameters for the validation.
AS is a reliable maximal activity scale and widely
sed for the evaluation of functional status in
atients with heart failure [13,19—22]. The MRF28
otal score, ‘daily activity,’ and ‘invalidity’ were
orrelated with almost all domains of WHOQOL
uestionnaire, NYHA functional class, and SAS. In
ontrast, ‘cognition’ was correlated only with the
HOQOL ‘psychological’ (R = 0.41) and ‘physical’R = 0.41) domains. The Spearman’s correlation
oefﬁcient between MRF28 and NYHA or SAS is less
han 0.40. Thus, ‘cognition’ may be able to eval-
ate different aspects of QOL from ‘daily activity’
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and ‘invalidity.’ In the clinical setting, there was
shown to be a weak correlation between BNP and
exercise capacity [23,24]. Similarly, the MRF28
total score was weakly correlated with BNP in this
study. MRF28 total score was also correlated with
SpO2; this could be possibly due to the inclusion of
some patients with acute exacerbation of chronic
heart failure in the present study.
Several approaches to determine QOL in heart
failure patients were based on 5- to 7-point scales.
Therefore, they are time-consuming and difﬁcult
to judge by themselves especially in patients with
severe dyspnea. In contrast, the MRF28 was conven-
tionally used for patients with respiratory failure
[8—10], and it is easier and less time-consuming to
answer the MRF28 by a yes or no [11]. A simpliﬁed
questionnaire is advantageous to evaluate QOL in
clinical practice.
Because ‘cognition’ is one of the important daily
behaviors, cognitive dysfunction should inﬂuence
QOL. Moreover, cognitive impairment was related
to higher in-hospital mortality in patients with
heart failure [25]. In other studies, cognitive func-
tion was signiﬁcantly impaired in cardiac transplant
candidates or older patients with lower ejection
fraction, and recovered to normal by cardiac trans-
plantation [26,27]. However, no QOL questionnaire
for heart failure addresses cognition at all. The
questions of ‘cognition’ examine whether patients
feel memory disturbance or lack of concentration
in daily life. Thus, it is worthy to contain these
questions in MRF28.
In this study, the total score of the MRF28 was
able to discriminate between NYHA classes III and
IV functional status. In another study, however, the
chronic heart failure questionnaire, the Minnesota
Living with Heart Failure Questionnaire and the
short-form 12 (SF-12) were not sufﬁciently sensi-
tive to discriminate between patients with NYHA
classes III and IV [4]. In the validation of Kansas City
Cardiomyopathy Questionnaire, the overall score in
patients with class III was not better than in those
with class IV in no anemic heart failure patients [5].
Thus, the MRF28 could be useful to classify health-
related QOL in mild to severe heart failure patients.
It is ideal that the questionnaire is applicable for
all patients from NYHA classes I to IV. In MRF28,
however, it is difﬁcult to discriminate between
NYHA classes I and II. One possible reason is that
the MRF28 is answered with 2-point scale: graded
scoring, like a 5-point scale, might detect the dif-
ference between asymptomatic patients and mild
symptomatic patients. Another possible reason is
that several questions did not constitute meaning-
ful factors for the evaluation of QOL in patients
with heart failure. Such questions of MRF28may dis-
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urb the function of discrimination between NYHA
lasses I and II. When the proportions of answered
yes’ were compared between NYHA classes I and
I in 28 questions, we found that it was higher in
YHA I than in NYHA II in 5 questions (cognitive
unction 3, invalidity 5, others 1, 2 and 3). Although
he difference in total score between NYHA classes
and II did not reach statistical signiﬁcance even
fter the deletion of these 5 questions, p-value
as improved. Thus, additional modiﬁcation should
e considered if we use MRF28 for heart failure
atients with mild symptoms.
Fatigue is also a common symptom to reduce
he exercise tolerance and QOL. A problem is that
riginal MRF28 does not include questions about
asy fatigability. However, we found that the score
f ‘daily activity’ was highly correlated with SAS,
hich is a semi-quantitative variable to evaluate
xercise tolerance [13]. In this study, we used a
odiﬁed MRF28, which deleted the words ‘lung’
nd ‘respiratory’ from the questionnaire to apply
t to patients with heart disease. This modiﬁca-
ion may allow us to evaluate the daily activity as
measure of exercise intolerance due to not only
yspnea, but also easy fatigability.
imitations
he present study was limited for several rea-
ons. First, we did not evaluate exercise functional
apacity by cardiopulmonary exercise test or
-min walk test. However, we employed an alter-
ative, functional variable, because SAS is a
emi-quantitative variable to evaluate exercise tol-
rance and correlates well with peak VO2 (R = 0.78)
13].
Second, this study included patients with mul-
iple degrees of heart diseases including ischemic
eart disease, cardiomyopathy, and postoperative
tate. In this study, however, we were able to con-
rm the correlations between MRF28 total score
nd SAS or BNP. When we limited this issue to the
atients with lower ejection fraction (<0.50), the
esult was unchanged (data not shown).
Third, we applied this questionnaire to 17
atients of NYHA class IV; 5 patients had chronic
eart failure, and 12 patients had acute exacer-
ation of chronic heart failure. Longer duration
f heart failure might induce psychosocial impair-
ent, invalidity, or impaired cognition. On the
ther hand, sustained hypoxia could suppress the
ensation of dyspnea in humans [28]. In fact, there
ere no signiﬁcant differences between NYHA III
nd IV in terms of subscores of ‘cognition’ and ‘inva-
idity.’ Thus, the interpretation of QOL in NYHA IV
hould be performed cautiously.
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Finally, this was not designed as a multicenter
tudy. The total number of patients was relatively
mall. Additional patients are required to draw a
eﬁnitive conclusion.
Although limited for these reasons, this study
llowed us to gain additional information about QOL
n patients with heart failure. Further study may be
arranted to examine whether subscores of MRF28
ould respond to variable treatments in patients
ith different etiologies of heart failure.
ppendix A. The ‘‘Maugeri Foundation’’
espiratory Failure (MRF28) item set, as
ubdivided by principal components
nalysis
.1. Daily activity
1. Washing myself (face), usually makes me feel
breathless.
2. Combing my hair or shaving myself usually
makes me feel breathless.
3. Getting dressed usually makes me feel breath-
less.
4. Because of my (lung) disease, I am unable to
shower as I would like to.
5. Because of my (lung) disease, I cannot put on
my socks, stockings, or shoes as I would like to.
6. Because of my (lung) disease, I am not able to
cook as I would like to.
7. Because of my (lung) disease, I cannot do
housework or light repairs around the house.
8. Because of my (lung) disease, when I need to,
I cannot bend over as I would like to.
9. Because of my (lung) disease, when I need to,
I cannot pick up light things as I would like to.
0. Because of my (lung) disease, I cannot play with
children as I would like to.
1. Because of my (lung) disease, I cannot talk as
much as I would like to.
.2. Cognition
. I forget names now more than I used to.
. I am very absent minded.
. When I am talking, I often forget what I wanted
to say.
. Even when something interests me very much I
cannot maintain concentration as long as I would
like to..3. Invalidity
. Because of my (lung) disease, I have become an
invalid.125
. Because of my (lung) disease, everything seems
too much of an effort.
. Because of my (lung) disease, I go out to see
friends or acquaintances less than usual.
. Because of my (lung) disease, I spend much more
time alone.
. Because of my (lung) disease, when I am outside
I feel I need to have someone with me.
.4. Others
. I feel tired in the morning.
. I feel unrefreshed in the morning.
. I feel irritable during the daytime.
. I think my respiratory problem is incurable.
. Because of my (respiratory) disease, I feel that
I am a burden to my family.
. Because of my (respiratory) disease, I avoid
going shopping.
. Standing up makes me breathless.
For patients using respiratory device only.
. My (respiratory) device interferes with my life a
lot.
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